NeOnc Technologies Holdings, Inc. Common Stock

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing central nervous system therapeutics designed to address the persistent challenges of overcoming the blood-brain barrier. The company's NEO drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. Its proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various cancer types and in clinical trials treating malignant gliomas. NeOnc's lead programs include NEO100, a proprietary formulation of purified perillyl alcohol administered intranasally, which is being evaluated in multiple Phase 1 and Phase 2 clinical studies for recurrent and progressive high-grade gliomas in both adult and pediatric populations. NEO100 holds FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations. NEO212 is an oral perillyl alcohol-temozolomide conjugate that has completed Phase 1 dose escalation and is advancing toward Phase 2 development. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products for multiple uses including oncological and neurological conditions. NeOnc is pre-revenue and funds operations through equity offerings and credit facilities. Updated Aug 10, 2026